Cited by 11Treatment of Major DepressionElectroconvulsive Therapy StudiesPharmacovigilance and Adverse Drug Reactions

Citalopram withdrawal symptoms

Open access
Benazzi, F·1998·European Psychiatry

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0924-9338(98)80007-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Discontinuation syndromes subsided within a month in all but 3 patients (27%) in the Fava et al. study.

    “Discontinuation syndromes subsided within a month in all but 3 patients (27%).”

    From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [50]

    In the letter “Citalopram withdrawal symptoms” (page not provided), Benazzi reports that one patient’s symptoms disappeared after a week, supporting only the general point that symptoms can subside within a month. The letter does not report a Fava et al. study or the claim that three patients (27%) still had symptoms after a month. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Nine of 20 patients (45%) with panic disorder and agoraphobia who had remitted upon behavioral treatment experienced a discontinuation syndrome according to specific criteria based on the DESS after gradual tapering of SSRI.

    “Nine of 20 patients (45%) experienced a discontinuation syndrome according to specific criteria based on the DESS.”

    From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [50]

    The letter “Citalopram withdrawal symptoms” (page not provided) describes one patient who developed symptoms suggestive of a discontinuation syndrome despite slow tapering. It does not report a group of 20 patients, nine cases (45%), behavioral treatment, or DESS-based criteria. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • There are anecdotal reports on the use of clonazepam and other benzodiazepines or mood stabilizers for SSRI withdrawal.

    “There are anecdotal reports on the use of clonazepam and other benzodiazepines or mood stabilizers, which, however, need to be properly tested [15,50,59,62,72] .”

    From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [50]

    In “Citalopram withdrawal symptoms” (page unavailable), the case report describes a patient taking alprazolam and valproate when citalopram was discontinued and withdrawal symptoms appeared. It does not describe those drugs as treatments for withdrawal, mention clonazepam, or assess whether such treatments need testing. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Bhanji et al. and Fava et al. documented the persistence of symptoms up to 1 year following paroxetine discontinuation.

    “Bhanji et al. [59] and Fava et al. [50] documented the persistence of symptoms up to 1 year following paroxetine discontinuation.”

    From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [50]

    The letter ‘Citalopram withdrawal symptoms’ (page unavailable) mentions that paroxetine can cause discontinuation symptoms, but does not discuss symptoms persisting for a year or findings by Bhanji et al. or Fava et al. Its reported case concerns citalopram, with symptoms disappearing after one week. Searches for paroxetine, the named authors, and year-long persistence found no passage addressing the attributed finding. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Benazzi, F.
Affiliations
Ospedale G.B. Morgagni - L.Pierantoni (IT)
Corresponding author
Benazzi, F
Venue
European Psychiatry
Published
1998-07
Volume
13
Issue
4
Pages
219-219
ISSN
  • 0924-9338 (ISSN-L)
  • 1778-3585
OpenAlex
W2023711818
Cited by
11
References
5
Citations by year
2015: 2
FWCI
1.23
Type
journal article
Language
en
Open access
Locations
  • European Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
citalopram, drug withdrawal symptoms, selective serotonin reuptake inhibitors, antidepressant discontinuation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review